Expert argues psychedelics too unruly for traditional product development

Investor appetite in corporate psychedelia is returning, but the sector faces fundamental barriers to profitability, according to new research.

Continue Reading


News Source: medicalxpress.com

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *